Department of chemistry, Graduate school of science
I am currently conducting research on targeted alpha-ray therapy (TAT), in which alpha-ray emitting radionuclides are administered into the body to treat cancer. TAT has attracted much attention in recent years, and Osaka University is working on the development of a new drug using 211At as an α-ray emitting nuclide. 211At has a short half-life of 7.2 hours and mainly emits α-rays during the decay process, so when it is accumulated specifically in tumors, there is a little invasion of normal cells, and it is expected to enable treatment on a walk-in basis. In 2021, a investigator initiated trial of 211At for refractory thyroid cancer has been initiated. As a member of the 211At research team, I am conducting research to develop novel 211At-labeled functional molecules and to elucidate the immune activation mechanism induced by 211At injury.
I would like to contribute this research to society by interacting and exchanging ideas with many researchers to deepen my knowledge.